AstraZeneca的TRUQAP显示,在治疗侵略性前列腺癌方面取得了显著进展,存活率有所提高。 AstraZeneca's TRUQAP showed significant progress in treating aggressive prostate cancer, with better survival rates.
AstraZeneca的新治疗——TRUQAP(TRUQAP),加上腹膜和蛋白脱氧疗法,与标准治疗相比,大大改善了特定类型侵袭性前列腺癌患者的无进展存活率。 AstraZeneca's new treatment, TRUQAP, combined with abiraterone and androgen deprivation therapy, significantly improved progression-free survival in patients with a specific type of aggressive prostate cancer compared to standard treatment. 治疗显示,在总体存活方面,早期结果大有希望,并且具有一贯的安全特征。 The treatment showed promising early results in overall survival and had a consistent safety profile. 数据将在即将举行的一次医疗会议上介绍,并与监管者分享。 The data will be presented at an upcoming medical meeting and shared with regulators.